"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 4 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 2 | 5 |
| 2008 | 10 | 2 | 12 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 3 | 6 |
| 2012 | 5 | 5 | 10 |
| 2013 | 3 | 4 | 7 |
| 2014 | 9 | 0 | 9 |
| 2015 | 5 | 2 | 7 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 1 | 6 |
| 2018 | 5 | 1 | 6 |
| 2019 | 4 | 0 | 4 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 1 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. J Immunother Cancer. 2023 02; 11(2).
-
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. Melanoma Res. 2022 04 01; 32(2):88-97.
-
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
-
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. Eur J Cancer. 2021 11; 157:493-510.
-
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest. 2022 Jul; 51(5):1498-1514.
-
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
-
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas. Sci Adv. 2021 03; 7(13).
-
RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
-
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2020 12; 1(12):1204-1217.
-
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282.